GDD to build world's pioneer platform in mycology

Guangzhou Development District (GDD) has signed a cooperation agreement with Gilead Science Inc and Richardson Bio-Tech on Jan 20 to co-build the Guangzhou Gilead China-Richardson Innovation Center in GDD to fill the gap of diagnostic detection of invasive fungi in China.

Gilead Science Inc is the 193rd Fortune 500 company that GDD has introduced to the area. It has gone through rapid development since entering into the Chinese market in 2017. The group will make full use of its innovation capacity and talent resources to make contributions to the center's construction.

Richardson Bio-Tech, a pioneer in fungal diagnostic detection around the world, settled down in Guangzhou International Bio-Island in 2019.

Currently, the project has conducted pre-clinical trial with several 3A-grade hospitals like Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and Zhujiang Hospital of Southern Medical University. It is expected that the project will increase the diagnostic rate of clinical fungal infection and offer precise treatment solutions to reduce mortality.

The innovation center will also set up an international alliance on invasive fungal studies to jointly establish an Asia clinical case database and a precision medical platform for deep fungal infection.

It is expected that the center will gather innovative technologies and talents in mycology from home and abroad to develop a whole industrial chain featuring disease prevention, diagnosis, and treatment. It is also expected to contribute to the design of a diagnosis and treatment standard in China.

GDD signs a cooperation agreement with Gilead Science Inc and Richardson Bio-Tech on Jan 20 to co-build the Guangzhou Gilead China-Richardson Innovation Center. [Photo by Xiao Kunhua]

Share - WeChat